Neuralstem, Inc. (Neuralstem) is a publicly held research focused biotechnology company, engaged in research, development and commercialization of regenerative medicines based on human neural stem cell technology. The company has developed its proprietary Human Neural Stem Cell technology that facilitates the isolation of central nervous system stem cells from tissue for the treatment of diseases related to central nervous system including Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinson`s Disease. Neutalstem seeks patent protection for its proprietary developments and currently holds three issued US patents and an issued patent in Australia. In December 2009, the company obtained approval from IRB to commence first ALS stem cell trial at Emory ALS Center. The treatment of the first patient recently, with Neuralstem`s spinal cord stem cells represents a significant milestone of the company. In addition, it has established collaborations with educational communities such as John`s Hopkins University and the University of California San Diego, for using it`s proprietary human spinal cord derived neural stem cells. Neuralstem is headquartered at Rockville in Maryland, the US.The company reported revenues of (U.S. Dollars) USD 0.00 during the fiscal year ended December 2008, whereas the company reported revenues of USD 0.31 million during the fiscal year ended 2007. The operating loss of the company was USD 11.83 million during the fiscal year 2008, as compared to an operating loss of USD 6.37 million during 2007. The net loss of the company was USD 11.83 million during the fiscal year 2008, as compared to a net loss of USD 6.17 million during 2007.